autologous tumor membrane vesicles vaccine

An autologous personalized tumor vaccine composed of tumor membrane vesicles (TMV) derived from the patient's own tumor cells, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous TMV vaccine, the antigenic proteins in the vaccine are presented to the immune system and activate antigen-presenting cells (APCs). This may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte responses against the patient's tumor cells that express these same antigens, thereby killing the tumor cells. TCMVs contain tumor proteins and surface antigens that can stimulate an immune response.